Clarion Research Group (CRG) is a start-up company that owns the license to two patent-pending platform technologies and one product that has been registered with the FDA. Our flagship product, OsteoXcell^TM induces bone formation. Quality bone formation is of significant clinical importance to the dental and orthopedic markets. Since late 2007, the founder of CRG, James Rutkowski, DMD, PhD, has been studying the clinically affects of CRG's product OsteoXcell-1000. In his dental implant practice, he has observed with the use of OsteoXcell that the bone formation occurs 60% faster; the bone quality is superior to current methods; and the growth of bone is more predictable. In addition to improved clinical results, the cost of OsteoXcell-1000 is one-tenth the cost of current dental implant site development.